Angela Jia, MD, PhD, University Hospitals Seidman Cancer Center, Cleveland, OH, gives an overview of two studies addressing therapeutic innovation in high-risk localized prostate cancer. A Phase III trial (NCT01436968) of CAN-2409, an oncolytic viral therapy, demonstrated improved disease-free survival when added to external beam radiation (EBRT) with or without short-course androgen deprivation therapy (ADT). Separately, a validated multimodal artificial intelligence (MMAI) model applied to STAMPEDE data (NCT00268476) identified patients most likely to benefit from adding androgen receptor pathway inhibitors, offering a potential biomarker-driven approach to personalize therapy and reduce overtreatment. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
